Pharmacogenetics of breast cancer treatments: a sub-Saharan Africa perspective
KC Nthontho, AK Ndlovu, K Sharma… - Pharmacogenomics …, 2022 - Taylor & Francis
Breast cancer is the most frequent cause of cancer death in low-and middle-income
countries, in particular among sub-Saharan African women, where response to available …
countries, in particular among sub-Saharan African women, where response to available …
The role of CYP2B6 516G> T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
The two non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz (EFV) and
nevirapine (NVP), are currently the core antiretroviral drugs for treatment of HIV in sub …
nevirapine (NVP), are currently the core antiretroviral drugs for treatment of HIV in sub …
[图书][B] Using Network-based Modeling to Implement Strategies for Reducing HIV Drug Resistance
JLC Burke - 2022 - search.proquest.com
Mathematical models have evolved to capture epidemiological and infectious disease data
and complex relationships between the disease, host, and environment. Infectious disease …
and complex relationships between the disease, host, and environment. Infectious disease …
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child …
RM Cuco, O Loquiha, A Juga, A Couto, B Meggi… - Plos one, 2022 - journals.plos.org
Introduction Prevention of mother to child transmission of HIV (PMTCT) is frequently
challenged by irregular access to more effective anti-retroviral therapy. Nevirapine single …
challenged by irregular access to more effective anti-retroviral therapy. Nevirapine single …
[PDF][PDF] UPLC-QTOF-MS 法探讨温肾清毒方对大鼠生殖器官中依非韦伦浓度的影响
陆珍珍, 王绍龙, 钟鹏程, 赵江月, 阮志, 李庆波… - 中国中西医结合杂志, 2021 - cjim.cn
摘要目的探索温肾清毒方“艾可清” 对大鼠生殖器官中依非韦伦浓度(EFV) 的影响. 方法24
只雄性SD 大鼠随机分为4 组, EFV+ 高剂量艾可清组, EFV+ 低剂量艾可清组, EFV 组及空白组 …
只雄性SD 大鼠随机分为4 组, EFV+ 高剂量艾可清组, EFV+ 低剂量艾可清组, EFV 组及空白组 …
[PDF][PDF] Evaluation of the effect of Artemisia Annua L. and Moringa Oleifera Lam. on CD4 count and viral load among PLWH on HAART at Mbarara Regional Referral …
SS Twinomujuni, EC Atukunda, JK Mukonzo… - 2022 - academia.edu
Background Initiation of HAART among people living with HIV (PLWH) having a CD4
count≤ 350cells/µl, produces poor immunological recovery, putting them at a high risk of …
count≤ 350cells/µl, produces poor immunological recovery, putting them at a high risk of …
Plasma levels of efavirenz and frequency of the CYP2B6 516G> T polymorphism in people living with HIV-1 in Mexico
MA Ortíz-Rodríguez, J Oaxaca-Navarro… - Die Pharmazie-An …, 2022 - ingentaconnect.com
Efavirenz (EFV) is a widely used antiretroviral, due to its safety, efficacy, and low cost.
However, plasma concentrations have been related with an increased risk of virological …
However, plasma concentrations have been related with an increased risk of virological …
Фармакогенетические эффекты однонуклеотидных полиморфизмов, влияющих на метаболизм антиретровирусных препаратов
АЯ Баженова, КО Миронов… - ВИЧ-инфекция и …, 2022 - hiv.bmoc-spb.ru
Аннотация Введение. Определение фармакогенетических особенностей при
назначении антиретровирусной терапии (АРТ) является важной составляющей …
назначении антиретровирусной терапии (АРТ) является важной составляющей …
[PDF][PDF] Cyp2b6 and Sult1a1 Single Nucleotide Polymorphism: Implication for Nevirapine-based Hiv Therapy Among Ghanaians
Background Nevirapine is used in many developing countries for the management of HIV-1
patients. Despite its usefulness, hypersensitivity reaction is a common complication that …
patients. Despite its usefulness, hypersensitivity reaction is a common complication that …
ВИЧ-ИНФЕКЦИЯ И ИММУНОСУПРЕССИИ
A Bazhenova, K Mironov, A Kravchenko… - ВИЧ-ИНФЕКЦИЯ И …, 2022 - elibrary.ru
Introduction. Identification of pharmacogenetic effects on antiretroviral therapy (ART) has
become an important milestone to reach in the advancement of personalised treatment for …
become an important milestone to reach in the advancement of personalised treatment for …